Pharmaceutical

EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage

The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.

Jul 28, 2024 - 04:00
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.
Read the original article

Tags:

Previous Article

FDA committee proposes overhaul of perioperative lung cancer trials 

Next Article

FDA approves Sun Pharma’s JAK inhibitor for alopecia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MSD signs Daiichi Sankyo in multibillion dollar deal to develop ADCs

MSD signs Daiichi Sankyo in multibillion dollar deal to...

Oct 21, 2023

Pharma casts a wide net to hook opportunities in metabolic disorders

Pharma casts a wide net to hook opportunities in metabo...

Aug 7, 2024

STAT+: Medicare wants to improve Alzheimer’s care, but sidesteps drug prices

STAT+: Medicare wants to improve Alzheimer’s care, but ...

Aug 1, 2023